Sexual Disfuncombination therapyion Combination Therapy Guidelines Who, How, and When?

There are two alternative models for combination therapy: both will likely be adopted within the model of sexual medicine, by different clinicians. First, working alone, PCPs, urologists, psychiatrists, and finally gynecologists will incorporate sex counseling with their sexual pharmaceutical armamentarium to treat sexual dysfunction. Sex Perelman counseling in this situation, is utilizing sex therapy schemes and techniques to overcome psychosocial resistance to sexual funcombination therapyion and satisfacombination therapyion (20). In a second model, the above clinicians will collaborate with nonphysician MHPs (sex therapists), resolving sexual dysfunction(s) through a coordinated multidisciplinary team approach to treatment. The clinical combinations will deviate corresponding to the facing symptoms, as well as the changing expertness of these health care providers. The utilization of these two different models will need three steps.

(i) The clinician first referred by the patient will view their involvement, training, and competence.
(ii) The bio-psychosocial hardness and complexness of the sexual dysfunction as a expression of both psychosocial and organic facombination therapyors will be evaluated.
(iii) The clinician in consideration of the two previous measures, together with patient preference, will determine who starts treatment, as well as, how and when to refer. The guidelines for handling the relative severity of the dysfuncombination therapyion will fundamentally be extended, but continue to match the type of treatment algorithm.

Categorizing Psychosocial Obstacles to Treatment

Whether or not a physician works alone, as in the first model, or as part of a multidisciplinary team, as in the second, will be partly accomplished by the psychosocial complexity of the case. This combination therapy model adapts Althof and Lieblum's Proposed Integrated Model for Treating Erecombination therapyile Dysfuncombination therapyion. Still, it must be emphasized that this author is recommending a combining therapy model for all sexual dysfunction. The treating clinician would diagnose the patient(s) as suffering from mild, moderate, or severe PSOs to thriving restoration of sexual funcombination therapyion and satisfacombination therapyion. This characombination therapyerization would be set on an assessment of all the accessible information acquired during the evaluation. This would include an appraisal of the issues therapyors. This judgment would fundamentally take on the psychosocial (cognitive, behavioral, cultural, and contextual) facombination therapyors predisposing, precipitating, and maintaining the sexual dysfunction. This would be a dynamic diagnosis, continuously reevaluated as treatment progressed. The consulted clinician would continue treatment and make referrals on the basis of progression obtained. These PSOs are categorized as follows:

1. Mild PSOs: No significant or mild obstacles to successful medical treatment.
2. Moderate PSOs: Some significant obstacles to successful medical treatment.
3. Severe PSOs: Substantial to overwhelming obstacles to successful medical treatment.

Sexual Dysfuncombination Therapyion Treatment Guidelines

Although no objecombination therapyive data determines the criteria for diagnosis these three PSO categories, they will become a useful heuristic device to assist clinicians know when to refer. For example, Severe PSOs may require psychotherapeutic and psychopharmacologic intervention prior to the initiation of treatment applying sexual pharmaceuticals in order to reestablish sexual funcombination therapyioning and satisfacombination therapyion. Most nonmedical MHPs will cooperate with physicians to augment their own treatments, as sexual pharmaceuticals are likely to offer an ever-increasing role in MHP's treatment strategies and armamentarium for sexual dysfunction. Additionally, this treatment matrix will provide a usable tool for sex therapist physicians (usually psychiatrists), when determining whether to treat themselves, or seek cooperative assistance.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Pills company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

New Sexual Pharmaceuticals - Identifying Psychosocial Barriers to Success

Significantly, pharmaceutical promoting and educational initiatives have changed the delivery of sexual medication services, especially in the United States. Specifically, these changes in practice patterns leaded in PCPs becoming the principal healthcare providers for men who present with a substantial complaint of erectile dysfunction, with urologists typically seeing the more resistant cases. MHPs seldom are the initial treating clinicians anymore. This both facilitates and adds to the problem of success and failure. The significant number of PCPs treating erectile dysfunction has dramatically enhanced the number of patients seen, and the accessibility of medical treatment. Regrettably, the history incurred by PCPs and urologists is frequently limited to an end-organ focusing, and fails to uncover substantial psychosocial barriers to successful restoration of sexual health. These obstacles or resistance constitute a large cause of noncompliance and nonresponse to treatment. These barriers manifest themselves in various levels of complexity, which individually or collectively must be understood and managed for pharmaceutical treatment to be optimized.

Only recently, have physicians started integrating sex therapy concepts, and established that resistance to lovemaking is often emotional. Clearly, medical treatments alone are frequently insufficient, in assisting couples resume a healthy sexual life. There are a mixture of bio-psychosocial obstacles to be recovered that add to treatment complexity. All of these variable quantities affect compliance and sex lives considerably, in addition to the function of organic etiology. There are multiple sources of patient and partner psychological resistance, which may converge to sabotage treatment: What is the mental status of both the patient and the partner and how will this affect treatment, no matter of the approach used? What is the nature and stage of patient and partner psychopathology (such as depression)? What are the attitudinal distortions causing unrealistic expectations, as well as end point functioning anxiety? What is the nature of patient and partner readiness for treatment? When and how should treatment start, and be acquainted into the couple's sex life? What is his approach to treatment seeking? What should be the pacing of intimacy resumption? The general man with erectile dysfunction waits 2-3 years, before trying assistance. By that time, a new sexual equilibrium has been rendered within the relationship, which may be resistant to the changes a sexual pharmaceutical introduces. Furthermore, although partner pressure is a essential driver for treatment seeking, some men who wanted treatment at their partner's initiation do not necessarily confide in them about the treatment. What is their emotional and attitudinal readiness for shift? The sexual history will offer information considering premorbid and current sexual desire. What is her motivation or desire for sex? What are her concerns regarding his safety? What are her belief systems regarding the treatment process which now enables coitus? Her compliance may be affected be her perception of the treatment being artificial or mechanical: Is it the sildenafil, or me? What is her health status (vaginal atrophy, etc.) and physical readiness for sex; her capability for lubrication and need for stimulation, etc.? We know from the Massachusetts Male Aging Study that oftenness of erectile dysfunction growths with age. We know that older men tend to have older, post-menopausal partners. Female partner's additional and sometimes complicated medical needs are often not dealt in the brief evaluation interview, often conveyed by the common physician. What are the applicable contextual stressors in the patient and partner's current life, such as work, finances, parents, and children, etc.? What is the couple's overall quality and harmony of relationship? Interpersonal issues impact outcome through a variety of manifestations? Intimacy blocks and power struggles may cause failure. What are the patient and partner's sexual script? Overtime, incompatible sexual scripts, interest, and arousal patterns may predetermine sexual dysfunction. For instance, PDE-5s require stimulus, for the man to react sexually; stimulation is often more than merely adequate friction. There are many various sexual scripts and a variety of unconventional forms of sexual arousal (homosexuality, sadomasochism, etc.), which may sabotage arousal. Additionally, over time, there are reality-based adjustments in a partner's sexual desirableness, which may also affect both arousal and orgasmic reaction.

Although most of these barriers to success can be managed as part of the treatment, too few physicians are prepared to do so. What is a model for this situation? These various sources of psychological resistance demonstrate themselves in a diverse manner, which Althof conceptualized as three scenarios of psychosocial complexity. Each level would lead to an alternative treatment plan. Importantly, this conception can be expanded to conceptualise treatment for all sexual dysfunctions, and regardless of who provides care they all would be CT.

Diabetes and The Importance of Following a Physician's Advice
Vasectomy - Planned Parenthood

New Sexual Pharmaceuticals - Success of the New Treatments

A phosphodiesterase type 5 inhibitor, often shortened to PDE-5 inhibitor, is a drug used to stop the degradative action of phosphodiesterase type 5 on cyclic guanosine monophosphate (cGMP) in the smooth muscle cells lining the blood vessels providing the corpus cavernosum of the penis. These drugs are applied in the treatment of erectile dysfunction, and were the first effective oral treatment accessible for the circumstance.

The new PDE-5 inhibitors have resulted in more people being treated than ever, with high success rates. There is much greater awareness of sexual and psychosexual issues surrounding dysfunction, simultaneous with a reduction of the stigma previously related with erectile dysfunction. Treatment is now led by an thriving number of facilitating professionals, primarily PCPs. Treating erectile dysfunction is now a billion-dollar business with millions of men treated and many helped.

Barriers to Treatment Success

Around 90% of men who seek help for erectile dysfunction are treated with PDE-5s, all of which are reasonably safe. All are entirely contraindicated with accompanying nitrate apply; with some additional warnings or contraindications related to use of alpha-blockers. Broadly, PDE-5 inhibitors are highly effective, restoring erections in 70% of men, yet there is a growing body of evidence suggesting that the frequently quoted 20 50% drop-out rate for medical treatments is true for PDE-5 treatment as well. Why? The contrary effect profile is superior for all three PDE-5s, with few patients terminating treatment, because of contrary events. Of course, not all discontinuance of sexual pharmaceuticals are due to failure or complications. There are some who tried the medications out of curiosity and never intended to continue utilizing a PDE-5. There are some reported cases of men with psychogenic erectile dysfunction experiencing a cure after temporary practice of a PDE-5.

Reciprocally, some people will stop PDE-5 because of the hardship of their erectile dysfunction. For these individuals, the pharmaceuticals simply don't work. Careless of the mode of administration, a certain percentage of the population will not see restored capability, because the degree of organicity is so Perelman profound as to overwhelm the salutary effects of the drug. In particular, some diabetics and radical prostatectomy survivors may require more powerful medical treatments.

Significantly, PDE-5 treatments do have profound psychosocial limits and results which have produced born-again roles for sex therapists, albeit more compound and advanced ones. Previously, many assumed that high discontinuation rates were due to the objectionable nature a specific treatment, such as self-injecting the penis. They thought that the introduction of efficacious and safe oral agents would reduce this high drop-out rate. However, there is great complexness to the barriers to success story. Although definitely improving, the reported success rate, the ensuing publicity (following PDE-5 launches) still resulted in just a small percentage of people worldwide receiving pharmaceutical therapy. Erectile dysfunction treatment, even with its juggernaut of publicity and advertising has penetrated ,15% of the estimated market place. In fact, industry information proposed that a geometrically small number of individuals were really successfully treated and fulfilled repeat customers . Obviously, a limited number of men were treated and a large percentage of those who tried it, apparently discontinued rather abruptly. There was also a high relapse rate when medication was stopped. The model for all three PDE-5s, as well as ICI and IUI treatments for erectile dysfunction, was chronic pharmaceutical use in order to relieve symptoms. To date, very little was published about weaning patients from pharmaceuticals or effectively maintaining them on smaller doses.

Medical Treatments for Erectile Dysfunction

The 1980s viewed a progressive change away from psychological handling of sexual disorders to an emphasis on surgical and medical solutions for bettering sexual health. Simultaneously, there was a advanced change within the medical community and public at large, towards regarding the etiology of sexual disorders as organic, instead than the psychogenic understanding underlined by sex therapists. Practice of improved advanced diagnostic procedures, such as duplex sonography and cavernosograms (although not inevitably bettering treatment) brought credibleness and imprimatur to the importance of organic pathogenesis. This was especially true in the area of erectile dysfunction, where urologists established authority, with the prosperous marketing and practice of different intracavernosal and intraurethral systems. Although highly touted by urologists, the treatment efficaciousness of these products was offset by their intrusiveness into the patients bodies and decrease in spontaneity, their practices of practice needed.

Initially, there were few oral treatments for erectile dysfunction, being used by urologists, such as yohimbine based products, trazodone, and bupropion. They had only average proerectile capability. Pharmaceutical companies were inspired to pursue oral treatments with the hope of less intrusiveness and even better profits. The first available prove of meeting that anticipate was the sildenafil launch. Accompanying to Pfizers success, many companies at the same time followed clinical tests of easy-to-use treatments for male sexual disorders. Among others, these included supplemental PDE-5 type compounds and other oral treatments, such as ixense, and topically applied compounds. Additionally, PT-141 (Palatin Technology, Cranbury, NJ, USA) is a nasally administered peptide that is under development, which is assumed to work through a central nervous system mechanism.

Presently, there are three highly impelling PDE-5, FDA-approved treatments for erectile dysfunction: sildenafil, vardenafil, and tadalafil. Reviews of long-term extension analyses and published accounts of usage in clinical practice show that sildenafil's strength was maintained with long-term treatment. Significantly Combination Therapy for Sexual Dysfunction better erectile function was demonstrated for sildenafil compared with placebo for all efficacy parameters examined, regardless of patient age, race, body mass index, erectile dysfunction etiology, erectile dysfunction severity, erectile dysfunction duration, or the presence of several co morbidities. Long-term effectivity was evaluated in three open-label reference studies. Vardenafil (launched in 2003) is a potent, selective PDE-5 inhibitor, which improved erectile function in a general population of men with erectile dysfunction and in characteristically challenging-to-treat groups such as diabetic and post prostatectomy patients. Tadalafil also launched in 2003, when taken, as needed ahead sexual activity and without limitations on food or alcohol intake, significantly better erectile function. It provided a essential proportion of patients to reach a normal IIEF erectile function domain score, exposed a broad window of therapeutic reactivity and was well supported in a representative population of patients with broadspectrum erectile dysfunction.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

Diabetes is Not Always Permanent
Increasing The Insulin Output

Sex Therapy

Sex therapy theory and proficiency were derived from the pioneering works of both Masters and Johnson and Kaplan. Initially Masters, a gynaecologist, applied an advanced 2 week, mixed-gender, co-therapy team, quasiresidential approach. Sex therapy quickly morphed into weekly sessions provided within a solo MHP s office established practice. Treatment retained to emphasize sensate focussing exercises and the reduction of functioning anxiety. By the 1980s, sex therapy contemplated a cognitive-behavioral theoretical oblique, while typically using Masters and Johnson variations, such as Kaplan s, four phase model of human sexual response: desire, excitement, orgasm, and resolution. The patterns were not necessarily simple and causes could become effects. For instance, an erectile dysfunction might cause reduced desire. Still, generally speaking, sex therapy was and is, the diagnosis and treatment of interruptions in any of these four phases or the sexual pain and muscular disorders. These dysfunctions took place independent of each other, however they often clustered.

Sex therapy was established on the development of a treatment plan conceptualised from the quick assessment of the quick and remote causes of SD while holding rapport with the patient. The sex therapist delegated structured erotic experiences carried through by the individual in the privacy of their own homes. These exercises were planned to correct dysfunctional sexual behaviour patterns, as well as positively altering cognitions regarding sexual positions and self-image. This home play altered the immediate reasons of the sexual issue, permitting the individual to have for the most part positive experiences and made a powerful impulse for prosperous treatment outcome. Interventions aimed at correcting or challenging maladaptive cognitions were incorporated into the treatment process. The individually tailored exercises acted as therapeutic investigations and were progressively altered until the individual or couple was step by step guided into fully working sexual behaviour. Still, each dysfunction had its own clump of fast causes. Certain exercises were typically used with a particular dysfunction. For example, almost all men with early ejaculation were instructed the stop start method, because failure to recognize and respond the right way to sensations predictive to orgasm, characterized that syndrome.

Patients might be single or coupled. The single patients were seen alone, but their new sexual partner might join them in treatment, once an ongoing relationship was formed. Couples were usually seen conjointly, still, during the rating stage of treatment, they were typically seen alone for at least one session of history taking. Other individual sessions were reserved for management of resistance where it may be more strategic to discuss the obstructions to success privately. To help the success of this quick approach, couples at times needed to explore other aspects of their relationship or intrapsychic life. Yet, building sexual harmony typically remained the primary focus. Despite the concrete goal preference, the therapeutic context was humanistic, emphasising good communication, intimate sharing, and mutual respect.

Sex therapy was an effectual treatment for primary anorgasmia in women, some erectile failure in men, and was probably effective for secondary anorgasmia, . . . , vaginismus in women and premature ejaculation in men. Perelman experience supported efficacy in treating hypoactive sexual want, sexual aversions, dyspareunia, and delayed orgasm in men. Despite its potency, there were and are drawbacks to this approach, especially from a cost-benefit standpoint. Although taken as a short-term treatment within a mental health context, it typically needed many appointments with a trained specialist and a high degree of motivation on the part of the patient. Historically, healthcare systems have discarded labor intensive, expensive approaches once easier and more rapid alternatives were available. Sex therapy receded as a treatment of choice during the 1990s, as medical and surgical approaches performed by urologists rendered hegemony over the treatment of erectile dysfunction, in special. The pinnacle of this conversion was reached during 1998, with the launch of sildenafil.

Sexual Disorders - Evolving Models

Most of the clinicians involved in the treatment and research of sexual dysfunctions are probably not very fulfilled with the current nomenclature, which is mostly unidimensional and not including all nuances and aspects of intimate issues. The nomenclature does not deal with psychological, relational, and situational factors of human sexuality. Some of these issues, particularly the ones referred to female sexuality.

A 26-year-old male who complains being distressed because ejaculating within 30 60 sec after penetration during sexual activity with his wife, but reports no quick ejaculation while masturbating technically meets the diagnostic standards for premature ejaculation. Nonetheless, the diagnosis of premature ejaculation does not in full account the scope and psychology of his sexual disfunction. The same could be implied in the case of 67-year-old married male who began to obsessively masturbate around 2 years ago. He thinks about other men being around at times while masturbating, or at times he masturbates just without any thoughts, in different places, for example, while driving. Is his diagnosis sexual disorder not otherwise specified? Or obsessive-compulsive disorder? Do these diagnoses-labels help the clinician in any way?

The recent diagnostic scheme, rephrasing Winston Churchill, is probably the worst diagnostic system except for all those that have been tried. It for certain could be improved. Recently, Fagan suggested a systematic way in which clinician organize the mass of information about sex. We discuss it in more details for two reasons it distinctly establishes that human sexuality, as other 6 Segraves and Balon areas, requires a more compound and advanced descriptive system, and it exemplifies one of probably many potential approaches.

Fagan suggests using the system of four perspectives, or four different ways to view a clinical case, which was originally developed by McHugh and Slavney (48) for all psychiatric disorders. He believes that these four perspectives are a more complex way of viewing clinical information and then communicating that information to clinicians, colleagues, and the individual with the clinical problem or disorder.

These four perspectives are:

1. The disease perspective
2. The dimension perspective
3. The behavior perspective
4. The life story perspective

The disease perspective is categorical, the patient either has or does not have the disease. As Fagan points out, this is the foundation of the medical model, but not the full story. This view turns to physiology, anatomy, and medicine to learn about patients sexual issue.

The dimension perspective focusing on measurement (dimensional gradation and quantification). Cases of the objects of measurements are intelligence quotient, behavioral patterns, mood, or personality traits.

The behaviour position focussing on the behavior of an individual who is goal directed, or teleological. Fagan explains that the behaviour position is to cognitive-behavioral clinician what the disease perspective is to physician.

Lastly, the life story perspective is what most people connect with psychotherapy. It relies on the narrative told by the patient to give some meaning and focusing to their life.

Fagan underlines that no single perspective is, in itself, more valuable than any other, and each perspective can contribute to the conceptualisation. His proposal assists, in part, to handle several issues. First, human sexuality is much more compound than just reaching reliable erection and, as noted, the medical diagnosis does not include psychological, relational, and other factors. Second, not all sexually disordered behaviour has a psychiatric diagnosis. Third, sexual diagnosis is an alternate and developing concept. Fourth, sexual diagnosis does not involve causality.

Fagan suggests that one should choose the primary perspective that best fits the patient and then integrate the other perspectives into the conceptualisation and treatment to make use of the complementary contributions they may provide. He as well emphasises that perspectives are conjunctive and not disjunctive.

Fagan feels that utilising the four perspectives is more accommodating in delineating sexual problems and conceptualising their handling. Many will probably find this proposal too composite or not compound sufficient, overly inclusive or not inclusive enough, not practical enough or too practical. Nevertheless, we feel that it is an fascinating and thoughtful proposal, which may further stimulate and help the argument about the diagnostic issues in the area of sexual dysfunctions.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

Diabetes and The Importance of Following a Physician's Advice
Diabetes is Not Always Permanent

Epidemiology of Sexual Dysfunction

Numerous population studies in this and other countries show a high prevalence of sexual problems in the general population. These reviews designate that 40% of women have evidence of psychosexual disfunction. The related number for men is 30%. We have more evidence relating the prevalence of sexual issues in men than women although the data base in both groups is rapidly rising. Correlates of erectile dysfunction in men include diabetes, vascular disease, age, and cigarette smoking. Serum dehydroepiandrosterone and high-density lipoprotein cholesterol were found to be negatively connected with erectile problems. Depression was connected with erectile function in cross sectional studies, whereas passive personality traits tended to predict who would develop impotence in a prospective study. Studies in other countries have, in general, found pretty alike rates of erectile disfunction in the same age population and also that erectile dysfunction tends to correlate with the presence of diabetes, higher age, cardiovascular disease, and depression.

It's essential to mark that depression is not the only mental disorder linked with sexual dysfunction(s). Sexual disfunction occurs in course of schizophrenia or anxiety disorders.

Many recent studies went beyond gathering complete epidemiological data and examined the impact of sexual disfunction on men suffering from different sexual dysfunctions. For instance, Moore et al. discovered that younger men suffering from erectile disfunction reported comparatively less relationship satisfaction, greater depressive symptomatology, more negative reactions from mates, and less job satisfaction than older men. They concluded that older men experience less difficulty than younger men adjusting to life with erectile dysfunction. Symonds et al. interviewed men with self-diagnosed premature ejaculation. In their relatively small sample, they discovered that men with premature ejaculation had a sense that premature ejaculation was stimulating (not exclusively) 4 Segraves and Balon lower self-esteem and had impact on forming a relationship. Determinations of these two studies underline the complexity of sexual dysfunctions/disorders and their link to an overall functioning and well-being.

A population study of US females aged 18 65 discovered that 33% of US females described low libido, problem with sexual climax, or trouble with lubrication for at least 1 month in the last year. Other surveys have described corresponding findings. Hawton examined sexual activity in a community sample in Oxford, United Kingdom and found that 17% reported never having an climax and only 29% reported feeling sexual climax at least 50% of the time. Marital satisfaction was the major predictor of intimate activity and satisfaction. Dunn also reported several population studies in the United Kingdom. Approximately 40% of the women reported a sexual issue, the most common being trouble reaching sexual climax. A recent population survey in Sweden of sexual behavior in women aged 18 74 discovered that the most general problems were low desire followed by sexual climax and arousal troubles. They also reported significant co-morbidity between sexual disorders. Some questioned the methodology of epidemiologic studies of sexual disfunction as too simplistic and medicalized.

Laumann et al. have recently completed a survey of 27,500 men and women aged 40 80 in 29 countries. In Northern European countries, deficiency of sexual desire was reported in 25.3% of women. issues with climax and pain were reported in 16.9% and 17.7%, respectively. In men, low libido was reported in 12%, erectile disfunction in 12%, and rapid ejaculation in 20.6%. Corresponding values were reported for other world regions, with small differences in prevalence among various regions.

Other Resources:
Natural Male Enhancement
Treatment of Sexual Disorders - Evolution of Current Treatment Approaches

Treatment of Sexual Disorders - Evolution of Current Treatment Approaches

In the 1960s, psychiatrical handling of sexual issues was preponderantly psychoanalytic psychotherapy. In the mid- to late-1960s, behavioural therapists started issuing clinical series documenting the successful treatment of sexual problems by the use of classical qualifying techniques. Indeed, the 2 Segraves and Balon start stop technique for the treatment of quick ejaculation was first named by Semans in 1956. Nevertheless, the major apply of behavioral techniques to handle sexual problems began after the publishing of Human Sexual Inadequacy by Masters and Johnson in 1970. In the 1980s, subject compositions began appearing in the psychiatrical literature about utilizing monoamine oxidase inhibitors and low dose antipsychotic drugs to address quick ejaculation. Yet, the use of psychiatrical drugs to address quick ejaculation became much more common after the introduction of the selective serotonin reuptake inhibitors.

Urologists have made great contributions to the treatment of erectile dysfunction. Both the Small-Carrion and inflatable penile prostheses were introduced in the 1970s. Although patents for vacuum erection devices were obtained as early as 1917, the introduction of the vacuum erection pump by Osborn in 1974 resulted in this being a common resolution for many men before the introduction of other treatment options. Alprostadil intracorporal injections were presented in the 1980s. However, the popularity of treatment approaches minimized dramatically with the introduction of sildenafil in 1998 and the later introduction of tadalafil and vardenafil. Nowadays a man could take an effective oral agent that provided sexual behavior to happen in a more natural way. Understandably, as the essential etiology of erectile dysfunction for majority of aging men is vascular, the main focusing of therapeutic directed research of erectile dysfunction has been the vascular dysfunction/insufficiency area. The previously touted use of androgenic hormones in erectile dysfunction has been deserted as it became clear that androgen administration does not better erectile dysfunction in eugonadal men. Interestingly, testosterone substitute in men with age-related mild hypogonadism is not effective in reversing symptoms of hypogonadism (in contrast to the same situation in older men).

The successful introduction of sildenafil contributed to the research forpharmacological treatments for female sexual disorders. Initially, many companiesdid clinical trials in women with substances that had established prosperous in treatingerection problems. Generally, these trials were unsuccessful. The one exception isa clitoral vacuum erection device, which has FDA approval. Another approach is the study of androgens to induce want in women. Off-label use of androgen preparations increased significantly after the work by Gelfand andSherwin demonstrated that supraphysiological levels of testosterone enhanced libido in postmenopausal women. The apply of androgen preparationsto handle desire problems in women is currently undergoing clinical trials. As Rosen pointed out, many large pharmaceutical trials of female sexual dysfunction areunfortunately impeded by various methodological issues, such as the deficiency of apply of physiological outcome measures and the lack of consensus classification system for female sexual dysfunction in determining inclusion and exclusion criteria.There is also no precise and stable definition of normal sexuality available. Definition is also of dubious clinical usefulness.

The lack of success in search for efficacious pharmaceutics for treatment of sexual dysfunction in women directed to the examination and use of variousTreatment of Sexual Disorders botanical or herbal, and other contents in these indications; for review see Ref. As Rowland and Tai caution us, the effects of herbals tend tobe limited, relatively nonspecific, poorly studied, and associated with unpredictableor unfamiliar side effects.

The recent focus on pharmacological and other biological handling of sexual dysfunction regrettably takes away attention and emphasis from psychological treatments. However, as Heiman points out, psychological treatments are efficacious (though their presented efficacy is frequently limited) and needed (for various reasons, such as optimisation of psychological treatments, patient choice, low frequency of side effects, etc.). Heiman alsocautions that the prescription of a physiologic treatment that disregards the fact that human sexuality is instilled with individual meaning may invite further interference with sexual functioning.

Other Resources:
Natural Male Enhancement
Diabetes and The Importance of Following a Physician's Advice

Diabetes and The Importance of Following a Physician's Advice

The onset of diabetes is marked by intense thirst, the drinking of huge quantities of water, and a corresponding excessive urine output. All B vitamins including vitamin B and many other nutrients- are readily lost in the urine; and the more urine excreted, the greater the losses. Though vitamin B6 may have been temporarily lacking before the onset of the disease, such a deficiency would thus immediately be made worse. Excessive urine production also rapidly induces a magnesium deficiency.

Even after insulin is given, sugar frequently spills into the urine. To dilute this sugar, water is withdrawn from the blood, and again excessive urine is formed. Much needed vitamin B6 and other nutrients which readily dissolve in water are therefore lost whenever the urine shows a positive test for sugar . A person whose diabetes is not well controlled might thus easily have vitamin-B6 and magnesium deficiencies even though his intake appears to be adequate.

When the pancreas has been so damaged that it can no longer produce sufficient insulin, sugar can neither enter the cells nor be changed into body starch or fat. Sugar coming from digesting foods therefore accumulates in the blood until, when perhaps three or four times above normal, it spills into the urine. Conversely, insulin given to a person with diabetes causes the sugar to pass into the cells and the amount in the blood to fall. The quantity of insulin needed, however, varies with each individual and from time to time, depending largely on the carbohydrate intake. If too much insulin is given or too little food eaten, the symptoms Ii of low blood sugar-weakness, nervousness, wooziness, perhaps headache, trembling hands, and loss of consciousness, I or blackout--can be brought on with such lightning speed that they are spoken of as an insulin reaction, or insulin shock. To prevent such a reaction, the quantity of food prescribed by the physician must be eaten.

Whenever the blood sugar drops below normal, the alarm reaction of stress is set off. The adrenal hormones cause body protein to be broken down into fat and sugar and still more fat from storage depots to be released into the blood. If insulin is still excessive, this sugar also enters the cells too quickly; the blood sugar is again reduced, and further proteins are destroyed. Simultaneously the blood fats, unusually excessive in persons with this disease, soar even higher; in diabetics with atherosclerosis, the stage is set for a heart attack.

To prevent insulin shock, needless destruction of body protein, and excessive blood fat, a doctor carefully balances the type and amount of food recommended against the insulin dosage.

If insufficient insulin is given, sugar cannot enter the cells. Certain acids and acetone, formed from incompletely utilized fat, accumulate in the body and cause acetone acidosis. The acids are neutralized by combining with sodium and potassium, and the salts thus formed are excreted in the urine. Acetone, gives a characteristic odor to the breath of patients with uncontrolled diabetes. Even mild acidosis can cause headache, fatigue, nervousness, and nausea. Severe acidosis can rob the body of so much potassium that unconsciousness, or diabetic coma, and even death can result. Because it is difficult for patients to adhere to strict diets, physicians have sometimes attempted to adjust the insulin dosage to the foods diabetics select for themselves. Such freedom, however, has usually proved to be disastrous. More than go per cent of patients allowed "free diets" have been found to develop serious complications in a relatively short time.

A diabetic skis a slalom course between insulin shock and diabetic coma. A physician, however, can prevent both of these reactions provided the patient follows his directions. Any changes made to improve the nutritive value of food eaten must be done within the framework of the diabetic diet he recommends.

Although diabetic specialists are expert in adjusting insulin dosage to the diet recommended, it is a tragic fact that few have become sufficiently interested in nutrition to make an all-out effort to stimulate maximum insulin production or to prevent devastating complications.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.

Increasing The Insulin Output

It has long been known that if the nutritional needs of a diabetic can be reduced, the disease sometimes disappears. If a diabetic has been under stress and the stress is removed-for instance, a sick child who caused worry has recovered -he may no longer need insulin. Overweight diabetics can frequently stop insulin after reducing. In each of these cases, the body requirements have decreased, and the effect is the same as if the diet were improved.

Adequate nutrition stimulates insulin production in a variety of ways. The insulin output has often increased after diabetics have taken vitamin C; and guinea pigs given too little vitamin C produce insufficient insulin, have high blood sugar, and lose sugar in the urine. This vitamin is needed before several amino acids that form insulin can be utilized. Deficiencies of protein, pantothenic acid, and particularly vitamin B2 reduce insulin synthesis in rats; and conversely, generous amounts of these nutrients stimulate insulin production, as does a factor in yeast. A lack of vitamin B12 or potassium causes rats to have prolonged high blood sugar. Cortisone injections normally increase insulin production, but such an increase cannot occur if vitamins B1, B12 and pantothenic acid are deficient.A wide variety of animals develop diabetic symptoms when given 2 meals daily but not if allowed to eat frequently.

Diabetic patients have improved remarkably and many have been taken entirely off of insulin when 300 to 600 units of vitamin E have been given daily. Results have been especially striking when 3 tablespoons or more of lecithin were taken daily with vitamin E. Natural insulin production has been increased by giving patients vitamin B1, vitamin C unusually large amounts of protein, pantothenic acid, and small frequent meals each containing some carbohydrate.

After diabetes has been diagnosed, the diet should be made. As long as any pancreatic cells are able to produce insulin, the emphasis should be on keeping these cells healthy and on helping them to increase insulin production. The conclusion that diabetes is permanent is justified only when the insulin-producing cells have been largely or completely destroyed.

Nutritional needs are high. The dietary requirements of a diabetic are undoubtedly many times greater than those "of a healthy individual. Because the urinary losses of water-soluble nutrients are unusually high, to improve health the diet must more than compensate for these losses. For example, inositol was isolated from diabetic urine over 100 years ago; and the urinary losses of this vitamin are much greater than in other persons, a fact that contributes to the tragic incidence of severe atherosclerosis. Both the urinary losses and the requirements of magnesium and vitamin B are markedly increased. Although the National Research Council considers : milligrams of vitamin B adequate for adults, conscientious objectors obtaining this quantity from army rations excreted excessive amounts of xanthurenic acid.

Every time when acidosis develops or the blood sugar falls below normal an alarm reaction to stress is set off, increasing the need for protein, vitamin C, pantothenic acid, potassium, and other nutrients. Cortisone given as a medication, which simulates the body's reaction to stress, has caused both diabetes and inflammation of the pancreas in patients.

If pantothenic acid is undersupplied, the blood sugar drops so quickly after insulin is given that the danger of insulin shock, or a blackout, is tremendously increased.

Certain individuals, known as "brittle" diabetics, are so unusually sensitive to insulin that their blood sugar falls rapidly from extremely high to extremely low, causing insulin shock to be common. This condition appears to result largely from a deficiency of pantothenic acid, though brittle diabetics also have unusually high requirements for potassium, protein, vitamins B2 and C, niacin amide, and lecithin. When these nutrients have been increased, the sensitivity to insulin has disappeared.

Similarly, when diabetic diets have appeared to be adequate in vitamin B1, neuritis has developed, and was relieved as soon as larger amounts of this vitamin were given. Vitamin B1 is said to be especially valuable in preventing damage to the brain during diabetic acidosis. The more insulin needed, the higher is the requirement for vitamins B1, pantothenic acid, and biotin. Because of stress, urinary losses, and destruction by saccharine and other artificial sweeteners, the vitamin-C requirement is also unusually high in diabetes, and huge amounts of this vitamin sometimes bring unexpected results.

Diabetic patients are frequently deficient in potassium, which, though needed to utilize sugar, drops far below normal when the blood sugar falls or acidosis develops. The loss of potassium caused by salt retention during stress is especially dangerous to diabetics who suffer from high blood pressure or heart disease and increases the likelihood of a heart attack. Because a potassium deficiency can also be induced by eating too much salt, diabetics should not eat such foods as ham, smoked fish, and salted nuts when under stress or spilling sugar unless they take potassium. During severe acidosis a lack of potassium can be fatal. Low blood potassium also has been found to increase to normal if magnesium is given.

When diabetic patients with coronary disease have been given 2 to 5 grams of potassium chloride by mouth before an insulin injection, it has prevented an excessive drop in blood sugar and an increase in blood pressure and pulse rate; when given after the blood sugar fell, blood pressure and pulse have immediately decreased and the blood sugar and electrocardiograms quickly changed toward normal. It is probably wise for diabetics to use-with their doctor's permission-potassium chloride generously as a salt substitute and to carry I-gram tablets of potassium chloride to take at the first indication of insulin shock. If either stress or a pantothenic-acid deficiency has been prolonged, however, ordinary table salt (sodium) is needed rather than potassium.

About The Author

David Crawford is the CEO and owner of a Male Enhancement Pills company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.